Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in transgenic mouse models of frontotemporal lobar degeneration and Alzheimer's disease

Translational Neurodegeneration

Volumn 2, Issue 1, 2013, Pages

  Ho, Shuk W ^a   Tsui, Yuk Tung C ^b   Wong, Ting T ^b   Cheung, Stanley Kwok Kuen ^a   Goggins, William B ^c   Yi, Lau M ^c   Cheng, Kwok K ^c   Baum, Larry ^c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Dementia; Mouse; Plaques; Tangles

Indexed keywords

AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; HEAT SHOCK PROTEIN 90; TANESPIMYCIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG MEGADOSE; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HIPPOCAMPUS; MEDULLA OBLONGATA; MORTALITY; MOTOR PERFORMANCE; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN FUNCTION; ROTAROD TEST;

EID: 84890613378     PISSN: None     EISSN: 20479158     Source Type: Journal    
DOI: 10.1186/2047-9158-2-24     Document Type: Article

References (64)

1. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009, 110:1129-1134. 10.1111/j.1471-4159.2009.06181.x, 19457065.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356. 10.1126/science.1072994, 12130773.
3. Newell KL, Hyman BT, Growdon JH, Hedley-Whyte ET. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol 1999, 58:1147-1155. 10.1097/00005072-199911000-00004, 10560657.
4. Ubhi K, Masliah E. Alzheimer's disease: recent advances and future perspectives. J Alzheimers Dis 2013, 33(Suppl 1):S185-S194.
5. Cheng B, Gong H, Xiao H, Petersen RB, Zheng L, Huang K. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases. Biochim Biophys Acta 1830, 2013:4860-4871.
6. Yam GH, Wang K, Jhanji V, Choy KW, Baum L, Pang CP. In vitro amyloid aggregate forming ability of TGFBI mutants that cause corneal dystrophies. Invest Ophthalmol Vis Sci 2012, 53:5890-5898. 10.1167/iovs.11-9068, 22850414.
7. Zhao HL, Sui Y, Guan J, He L, Gu XM, Wong HK, Baum L, Lai FM, Tong PC, Chan JC. Amyloid oligomers in diabetic and nondiabetic human pancreas. Transl Res 2009, 153:24-32. 10.1016/j.trsl.2008.10.009, 19100955.
8. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van SM, Gwinn-Hardy K, Paul MM, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000, 25:402-405. 10.1038/78078, 10932182.
9. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102. 10.1126/science.274.5284.99, 8810256.
10. Gotz J, Deters N, Doldissen A, Bokhari L, Ke Y, Wiesner A, Schonrock N, Ittner LM. A decade of tau transgenic animal models and beyond. Brain Pathol 2007, 17:91-103. 10.1111/j.1750-3639.2007.00051.x, 17493043.
11. Lee VM, Kenyon TK, Trojanowski JQ. Transgenic animal models of tauopathies. Biochim Biophys Acta 2005, 1739:251-259. 10.1016/j.bbadis.2004.06.014, 15615643.
12. Hoi CP, Ho YP, Baum L, Chow AH. Neuroprotective effect of honokiol and magnolol, compounds from Magnolia officinalis, on beta-amyloid-induced toxicity in PC12 cells. Phytother Res 2010, 24:1538-1542. 10.1002/ptr.3178, 20878707.
13. Cheng KK, Yeung CF, Ho SW, Chow SF, Chow AHL, Baum L. Highly stabilized curcumin nanoparticles tested in an in vitro blood brain barrier model and in Alzheimer's disease Tg2576 mice. AAPS J 2013, 15:324-336. 10.1208/s12248-012-9444-4, 3675736, 23229335.
14. Kayed R. Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease. Hum Vaccin 2010, 6:931-935. 10.4161/hv.6.11.12689, 20980799.
15. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, Inukai A, Doyu M, Sobue G. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 2005, 11:1088-1095. 10.1038/nm1298, 16155577.
16. Lu Y, Ansar S, Michaelis ML, Blagg BS. Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line. Bioorg Med Chem 2009, 17:1709-1715. 10.1016/j.bmc.2008.12.047, 2729088, 19138859.
17. Evans CG, Wisen S, Gestwicki JE. Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J Biol Chem 2006, 281:33182-33191. 10.1074/jbc.M606192200, 16973602.
18. Lai BT, Chin NW, Stanek AE, Keh W, Lanks KW. Quantitation and intracellular localization of the 85 K heat shock protein by using monoclonal and polyclonal antibodies. Mol Cell Biol 1984, 4:2802-2810. 369291, 6396506.
19. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003, 228:111-133.
20. Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Doyu M, Sobue G. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J Mol Med (Berl) 2006, 84:635-646. 10.1007/s00109-006-0066-0, 16741751.
21. Scheibel T, Weikl T, Buchner J. Two chaperone sites in Hsp90 differing in substrate specificity and ATP dependence. Proc Natl Acad Sci U S A 1998, 95:1495-1499. 10.1073/pnas.95.4.1495, 19060, 9465043.
22. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, Toft DO. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 1997, 272:23843-23850. 10.1074/jbc.272.38.23843, 9295332.
23. Powers MV, Workman P. Hsp90 inhibition as an anticancer strategy: Novel approaches and future directions. Therapeutic resistance to anti-hormonal drugs in breast cancer: New molecular aspects and their potential as targets 2009, 111-137. Dordrecht, Netherlands: Springer, Hiscox S, Gee J, Nicholson R.
24. Sakagami M, Morrison P, Welch WJ. Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases. Cell Stress Chaperones 1999, 4:19-28. 10.1379/1466-1268(1999)004<0019:BAHAAG>2.3.CO;2, 312914, 10467105.
25. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3:213-217. 10.1016/S1535-6108(03)00029-1, 12676580.
26. Bharadwaj S, Ali A, Ovsenek N. Multiple components of the HSP90 chaperone complex function in regulation of heat shock factor 1 In vivo. Mol Cell Biol 1999, 19:8033-8041. 84888, 10567529.
27. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998, 94:471-480. 10.1016/S0092-8674(00)81588-3, 9727490.
28. Horne BE, Li T, Genevaux P, Georgopoulos C, Landry SJ. The Hsp40 J-domain stimulates Hsp70 when tethered by the client to the ATPase domain. J Biol Chem 2010, 285:21679-21688. 10.1074/jbc.M110.113118, 2898438, 20448033.
29. Luo X, Zuo X, Zhou Y, Zhang B, Shi Y, Liu M, Wang K, McMillian DR, Xiao X. Extracellular heat shock protein 70 inhibits tumour necrosis factor-alpha induced proinflammatory mediator production in fibroblast-like synoviocytes. Arthritis Res Ther 2008, 10:R41. 10.1186/ar2399, 2453760, 18410682.
30. Nie Q, Du XG, Geng MY. Small molecule inhibitors of amyloid beta peptide aggregation as a potential therapeutic strategy for Alzheimer's disease. Acta Pharmacol Sin 2011, 32:545-551. 10.1038/aps.2011.14, 21499284.
31. Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 2009, 8:783-793. 10.1038/nrd2959, 2787232, 19794442.
32. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Nahman NS, Hutton M, Burrows F, Petrucelli L. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 2007, 117:648-658. 10.1172/JCI29715, 1794119, 17304350.
33. Dickey CA, Dunmore J, Lu B, Wang JW, Lee WC, Kamal A, Burrows F, Eckman C, Hutton M, Petrucelli L. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J 2006, 20:753-755.
34. Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard P, Chiosis G. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci U S A 2007, 104:9511-9516. 10.1073/pnas.0701055104, 1890525, 17517623.
35. Salminen A, Ojala J, Kaarniranta K, Hiltunen M, Soininen H. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease. Prog Neurobiol 2011, 93:99-110. 10.1016/j.pneurobio.2010.10.006, 21056617.
36. Dou F, Yuan LD, Zhu JJ. Heat shock protein 90 indirectly regulates ERK activity by affecting Raf protein metabolism. Acta Biochim Biophys Sin (Shanghai) 2005, 37:501-505. 10.1111/j.1745-7270.2005.00069.x, 15999212.
37. Jinwal UK, Miyata Y, Koren J, Jones JR, Trotter JH, Chang L, O'Leary J, Morgan D, Lee DC, Shults CL, Rousaki A, Weeber EJ, Zuiderweg ER, Gestwicki JE, Dickey CA. Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci 2009, 29:12079-12088. 10.1523/JNEUROSCI.3345-09.2009, 2775811, 19793966.
38. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 2001, 47:291-302. 10.1007/s002800000242, 11345645.
39. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998, 58:2385-2396.
40. Page J, Heath J, Fulton R, Yalkowsky E, Tabibi E, Tomaszewski J, Smith A, Rodman L. Comparison of geldanamycin (nsc-122750) and 17-allylaminogeldanamycin (nsc-330507d) toxicity in rats [abstract]. Proc Am Assoc Cancer Res Annu Meet 1997, 38:308.
41. Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Sobue G. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG). Ann N Y Acad Sci 2006, 1086:21-34. 10.1196/annals.1377.012, 17185503.
42. Fujikake N, Nagai Y, Popiel HA, Okamoto Y, Yamaguchi M, Toda T. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J Biol Chem 2008, 283:26188-26197. 10.1074/jbc.M710521200, 3258858, 18632670.
43. Rozas G, Guerra MJ, Labandeira-Garcia JL. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 1997, 2:75-84. 10.1016/S1385-299X(97)00034-2, 9438075.
44. Westermark GT, Johnson KH, Westermark P. Staining methods for identification of amyloid in tissue. Methods Enzymol 1999, 309:3-25.
45. van Belle G, Gibson K, Nochlin D, Sumi M, Larson EB. Counting plaques and tangles in Alzheimer's disease: concordance of technicians and pathologists. J Neurol Sci 1997, 145:141-146. 10.1016/S0022-510X(96)00236-5, 9094041.
46. Biernat J, Mandelkow EM, Schroter C, Lichtenberg-Kraag B, Steiner B, Berling B, Meyer H, Mercken M, Vandermeeren A, Goedert M. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J 1992, 11:1593-1597. 556608, 1563356.
47. Chen L, Baum L, Ng HK, Chan LY, Pang CP. Apolipoprotein E genotype and its pathological correlation in Chinese Alzheimer's disease with late onset. Hum Pathol 1999, 30:1172-1177. 10.1016/S0046-8177(99)90034-5, 10534164.
48. Zehr C, Lewis J, McGowan E, Crook J, Lin WL, Godwin K, Knight J, Dickson DW, Hutton M. Apoptosis in oligodendrocytes is associated with axonal degeneration in P301L tau mice. Neurobiol Dis 2004, 15:553-562. 10.1016/j.nbd.2003.12.011, 15056463.
49. Hanslick JL, Lau K, Noguchi KK, Olney JW, Zorumski CF, Mennerick S, Farber NB. Dimethyl sulfoxide (DMSO) produces widespread apoptosis in the developing central nervous system. Neurobiol Dis 2009, 34:1-10. 10.1016/j.nbd.2008.11.006, 2682536, 19100327.
50. Willson JE, Brown DE, Timmens EK. A Toxicologic Study of Dimethyl Sulfoxide. Toxicol Appl Pharmacol 1965, 7:104-112. 10.1016/0041-008X(65)90081-5, 14256595.
51. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008, 13:38-43. 10.1016/j.drudis.2007.10.007, 18190862.
52. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007, 25:5410-5417. 10.1200/JCO.2007.11.7960, 18048823.
53. Caplan AJ. What is a co-chaperone?. Cell Stress Chaperones 2003, 8:105-107. 10.1379/1466-1268(2003)008<0105:WIAC>2.0.CO;2, 514860, 14627194.
54. Falsone SF, Kungl AJ, Rek A, Cappai R, Zangger K. The molecular chaperone Hsp90 modulates intermediate steps of amyloid assembly of the Parkinson-related protein alpha-synuclein. J Biol Chem 2009, 284:31190-31199. 10.1074/jbc.M109.057240, 2781518, 19759002.
55. Aleardi AM, Benard G, Augereau O, Malgat M, Talbot JC, Mazat JP, Letellier T, Dachary-Prigent J, Solaini GC, Rossignol R. Gradual alteration of mitochondrial structure and function by beta-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J Bioenerg Biomembr 2005, 37:207-225. 10.1007/s10863-005-6631-3, 16167177.
56. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491. 10.1126/science.1058189, 11520987.
57. Zhao HL, Sui Y, Guan J, He L, Lai FM, Zhong DR, Yang D, Baum L, Tong PC, Tomlinson B, Chan JC. Higher islet amyloid load in men than in women with type 2 diabetes mellitus. Pancreas 2008, 37:e68-e73. 10.1097/MPA.0b013e3181788e18, 18815541.
58. Rapezzi C, Riva L, Quarta CC, Perugini E, Salvi F, Longhi S, Ciliberti P, Pastorelli F, Biagini E, Leone O, Cooke RM, Bacchi-Reggiani L, Ferlini A, Cavo M, Merlini G, Perlini S, Pasquali S, Branzi A. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 2008, 15:40-48. 10.1080/13506120701815373, 18266120.
59. Hornsten R, Pennlert J, Wiklund U, Lindqvist P, Jensen SM, Suhr OB. Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid 2010, 17:63-68. 10.3109/13506129.2010.483114, 20462364.
60. Behl C. Estrogen can protect neurons: modes of action. J Steroid Biochem Mol Biol 2002, 83:195-197. 10.1016/S0960-0760(02)00271-6, 12650716.
61. Galea LA, Spritzer MD, Barker JM, Pawluski JL. Gonadal hormone modulation of hippocampal neurogenesis in the adult. Hippocampus 2006, 16:225-232. 10.1002/hipo.20154, 16411182.
62. Wise PM, Dubal DB, Wilson ME, Rau SW, Liu Y. Estrogens: trophic and protective factors in the adult brain. Front Neuroendocrinol 2001, 22:33-66. 10.1006/frne.2000.0207, 11141318.
63. Baum LW. Sex, hormones, and Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2005, 60:736-743. 10.1093/gerona/60.6.736, 15983176.
64. Alvarez-de-la-Rosa M, Silva I, Nilsen J, Perez MM, Garcia-Segura LM, Avila J, Naftolin F. Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer's disease. Ann N Y Acad Sci 2005, 1052:210-224. 10.1196/annals.1347.016, 16024764.